The safety and cost of Gelofusine as a replacement fluid in therapeutic plasma exchange procedures – Feedback from low/middle-income countries | Synapse
March 3, 2026
The safety and cost of Gelofusine as a replacement fluid in therapeutic plasma exchange procedures – Feedback from low/middle-income countries
Key Points
Gelofusine serves as a cost-effective alternative for replacement fluid in plasma exchange procedures, supporting safety and reliability.
Key evidence shows that Gelofusine significantly reduces complications compared to other fluids in low-income settings.
Assessment using observational data across multiple low and middle-income countries highlights varied adoption of Gelofusine.
Findings suggest that considering Gelofusine may enhance therapeutic plasma exchange practices, particularly where resources are limited.